Eli Lilly (LLY) is experiencing significant momentum in the weight loss drug market, primarily driven by its GLP-1 class products, Mounjaro and Zepbound. The company has captured a dominant 60% market share in the U.S., with Mounjaro revenue soaring 125% to $8.6 billion and Zepbound up 80% to $4.1 billion. The recent approval and launch of its oral weight loss drug, Foundayo, has further bolstered its growth trajectory, attracting 20,000 patients in just one month, 80% of whom are new to GLP-1 therapies.
Lilly’s competitive edge lies in Foundayo’s convenience, as it does not require food restrictions, unlike Novo Nordisk’s oral Wegovy. This positions Lilly to expand its customer base and potentially capture more market share in the burgeoning GLP-1 segment. With ongoing advancements in its weight loss pipeline, Lilly is poised for continued revenue growth, making it an attractive prospect for investors looking for stability in the pharmaceutical sector.
Source: fool.com